$CNAT Could Be Positioned for a Surge? – Tale of the Tape


Why Conatus Pharmaceuticals (CNAT) Could Be Positioned for a Surge? – Tale of the Tape

Conatus Pharmaceuticals Inc. (CNAT) is a biotechnology company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CNAT’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Conatus Pharmaceuticals could be a solid choice for investors.

Current Quarter Estimates for CNAT

In the past 30 days, 1 estimate has gone higher for Conatus Pharmaceuticals while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 43 cents a share 30 days ago, to a loss of 35 cents today, a move of 18.6%.

Current Year Estimates for CNAT

Meanwhile, Conatus Pharmaceuticals’ current year figures are also looking quite promising, with 3 estimates moving higher in the past month, compared to only 1 lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.56 per share 30 days ago to $1.25 per share today, a move of 19.9%.

Bottom Line

The stock has also started to move higher lately, adding 19.9% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Please enter your comment!
Please enter your name here